ArticleThe Kaohsiung journal of medical sciences2026
WDR72 Drives Esophageal Squamous Cell Carcinoma Progression by Inhibiting Autophagy via the PI3K/Akt/mTOR Pathway.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with a high rate of recurrence and metastasis, necessitating the identification of novel therapeutic targets. WD repeat-containing protein 72 (WDR72) has been linked to various cancers, but its specific biological function and underlying mechanism in ESCC remain largely unexplored. Herein, we investigated whether WDR72 promotes ESCC progression by suppressing autophagy via the PI3K/Akt/mTOR pathway. We first analyzed WDR72 expression using GEO (GSE213565) and validated using the GEPIA public databases. WDR72 mRNA/protein levels were then examined in patient-derived ESCC tissues and cell lines (EC109, KYSE150). Loss- and gain-of-function models (shRNA knockdown and pcDNA3.1-WDR72 overexpression) were used to evaluate proliferation, clonogenicity, apoptosis, migration/invasion, and autophagy. PI3K/Akt/mTOR activity was examined by measuring PI3K, p-Akt, and p-mTOR, with pathway dependence tested using the dual PI3K/mTOR inhibitor BEZ235. In vivo tumor growth and metastasis were analyzed in xenograft and lung metastasis models. We found that WDR72 was significantly overexpressed in ESCC tissues and cell lines. WDR72 depletion suppressed malignant phenotypes in vitro and substantially inhibited tumor growth and metastasis in vivo. Mechanistically, WDR72 overexpression activated the PI3K/Akt/mTOR pathway (indicated by elevated p-Akt and p-mTOR levels) and concurrently suppressed autophagy (evidenced by decreased Beclin-1 and LC3-II/LC3-I ratio, and increased P62). Notably, the PI3K/mTOR inhibitor BEZ235 abolished the pro-malignant effects and reversed the autophagy suppression induced by WDR72 overexpression. Collectively, our findings establish that WDR72 acts as an oncogene in ESCC by promoting proliferation, survival, and metastasis via activating the PI3K/Akt/mTOR signaling to suppress autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.